Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Clinical trial NCT05498155 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05498155
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-07
- Primary completion
- 2024-11-20
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.